An Open-Label Trial in Genotype 2, 3, 4, 5 and 6 Hepatitis C-Infected Subjects to Evaluate the Antiviral Activity, Safety, Tolerability and Pharmacokinetics of TMC435350 Following 7 Days Once Daily Dosing as Monotherapy.
Phase of Trial: Phase II
Latest Information Update: 26 Sep 2014
At a glance
- Drugs Simeprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms OPERA-2
- Sponsors Janssen R&D Ireland
- 01 Oct 2010 According to a Medivir media release, the results of this trial will be presented at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD).
- 27 Apr 2010 Additional trial location (Ireland) identified as reported by ClinicalTrials.gov.
- 12 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.